Definitive Contract 75N93023C00042
Award Date 9/30/23
Potential Completion Date 9/29/28
Potential Value $5.9M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Missoula, MT 59802, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
24
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases awards Inimmune Corporation $1.99 million to develop a Synthetic Adjuvant System. The contract is a result of the agency's SBIR Phase II solicitation seeking proposals for research and development to advance NIH and CDC missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Placed in...
- This federal contract award for $18,472,563.99 was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Montana. The contract's objective is to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. Research under this definitive, cost-no-fee contract will contribute to the pipeline of new adjuvant leads that either exploit the innate immune system or act directly...
- This is a $598,808 firm fixed price Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Inimmune Corp. The contract is for research on adjuvant discovery for vaccines and for autoimmune and allergic diseases. Inimmune Corp is a biotechnology company with expertise in synthetic chemistry, drug formulation, and pharmaceutical manufacturing. They have received...
- The Department of Health and Human Services' National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,896,692 Vaccine Adjuvant Discovery Program (VADP) contract to the University of Montana. The 5-year contract, which has no set-aside designation, aims to identify, characterize, and advance novel synthetic adjuvants for use in combination with bacterial and fungal antigens to induce a safe and durable T-helper 17 (Th17) and/or Th17/Th1 immune response. The University of Montana...
- This is a $9,566,206 firm fixed price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Montana for the "Development of UM-1098: A Novel Synthetic TH17 Inducing Adjuvant and Delivery System". The contract does not have a set-aside designation. Major subcontractors include West Virginia University Research Corporation, Inimmune Corp, and the University of Chicago. The contract involves the development and evaluation of a novel...
- This $1.8 million firm fixed price contract was awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases to Inimmune Corp. of Missoula, Montana. The contract is for Phase II of the Small Business Innovation Research program topic 091 to develop a new Toll-like receptor 4 agonist for the treatment of allergic rhinitis. The research and development effort will be performed in Missoula from September 2021 through August 2023. This total small business...
- This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID) to Corixa Corporation, a foreign-owned, for-profit manufacturer of goods. The contract, valued at $12,969,028.00, is to establish a pipeline of new adjuvant leads. An adjuvant is a substance that enhances the body's immune response to an antigen. The contract is a definitive contract with a cost-no-fee pricing type and had an ultimate completion date of December 29, 2008. There was no...
- This is a $9,013,936.11 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health to the Icahn School of Medicine at Mount Sinai. The contract is part of NIAID's Vaccine Adjuvant Discovery Program and aims to identify novel adjuvant candidates that can be used to enhance the efficacy of human vaccines. The contract has no set-aside designation. Key subcontractors include The Scripps Research Institute,...
- This federal contract award, valued at $9,189,961.00, was granted to Institut De Formulation DES Vaccins (Ch) SA, operating as Vaccine Formulation Institute (Ch) LTD, a for-profit limited liability company based in Switzerland. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, for the Vaccine Adjuvant Discovery Program. This five-year definitive contract, running from September 2024...